{"nctId":"NCT01143090","briefTitle":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","startDateStruct":{"date":"2010-08"},"conditions":["Schizophrenia","Schizoaffective Disorder"],"count":149,"armGroups":[{"label":"Open Label","type":"EXPERIMENTAL","interventionNames":["Drug: Lurasidone HCl"]}],"interventions":[{"name":"Lurasidone HCl","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Subject has completed 6 weeks of treatment and all required assessments on the final study visit (Visit 8) of Study D1050289 (NCT01143077).\n\nExclusion Criteria:\n\n* Subject is considered by the investigator to be at imminent risk of suicide or harm to self, others, or damage to property.\n* Subject has a body mass index (BMI) greater than 40 or less than 18 kg/m2 (see Appendix 3 for BMI determination).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Adverse Events","description":"Proportions of subjects with AEs, SAEs, and discontinuations due to AEs.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy","description":"Long-term efficacy of lurasidone in subjects with schizophrenia or schizoaffective disorder who have completed Study D1050289","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":8,"n":148},"commonTop":["Nausea","Insomnia","Akathisia","Anxiety"]}}}